Karyopharm to Participate at Barclays Global Healthcare Conference

Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15 at 4:35 p.m. ET. The event will feature insights from the company’s senior management team. Investors can access a live webcast and accompanying slides on the company’s Investor website, with a replay available for 90 days post-event. Karyopharm is known for its pioneering SINE compound technology and its lead product, XPOVIO®, which is approved in multiple oncology indications.

News Market Reaction – KPTI

-1.27%

-1.27% Session move

In the trading session that priced this news, KPTI declined 1.27%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., March 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Barclays Global Healthcare Conference in a fireside chat on Wednesday, March 15 at 4:35 p.m. ET.

A live webcast of the fireside chat, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-barclays-global-healthcare-conference-301765085.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When is Karyopharm participating in the Barclays Global Healthcare Conference?

Karyopharm is participating on March 15, 2023, at 4:35 p.m. ET.

Where can I watch the Karyopharm fireside chat?

The fireside chat can be accessed live and later replayed on the Karyopharm Investor website.

What is Karyopharm's main product and its indication?

Karyopharm's main product is XPOVIO®, an oral exportin 1 (XPO1) inhibitor approved for multiple oncology indications.

What technology does Karyopharm specialize in?

Karyopharm specializes in SINE compound technology aimed at addressing nuclear export dysregulation in cancer.

How long will the Karyopharm conference presentation be available for replay?

The presentation will be available for replay for 90 days following the event.